Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.33 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CCL2 | P13500 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6053912 | 0.98 | BRD4 (0.36) | BRD4CCL2HTR2AHTR6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL8534598 | 0.84 | GPR3 (0.32) | BRD4CCL2HTR2AHTR6KDM4E | |
| Hydrochloric Acid SCHEMBL7615269 | 0.84 | BRD4 (0.35) | BRD4CCL2HTR2AHTR6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3627506 | 0.79 | HTR2A (0.37) | BRD4CCL2HTR2AHTR6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL1065901 | 0.79 | BRD4 (0.34) | BRD4CCL2HTR2AHTR6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7642388 | 0.77 | SIGMAR1 (0.32) | BRD4CCL2HTR2AHTR6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7641256 | 0.77 | HTR2A (0.33) | BRD4CCL2HTR2AHTR6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6463695 | 0.76 | SIGMAR1 (0.31) | BRD4CCL2HTR2ASIGMAR1KDM4E | |
| Hydrochloric Acid SCHEMBL441678 | 0.76 | BRD4 (0.30) | BRD4CCL2KDM4ECYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7643705 | 0.75 | HTR6 (0.32) | HTR2AHTR6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131705-A1 | Practical, Cost-Effective Synthesis of Ubiquinones | ZYMES, LLC | 2009-05-21 | — | — | US | disclosed |
| EP-1968608-A2 | PRACTICAL, COST-EFFECTIVE SYNTHESIS OF UBIQUINONES | Zymes, LLC (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20080086013-A1 | CARBOMETALLATION OF ALKYNES AND IMPROVED SYNTHESIS OF UNIQUINONES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2008019196-A2 | CARBOMETALLATION OF ALKYNES AND IMPROVED SYNTHSIS OF UBIQUINONES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007078679-A2 | PRACTICAL, COST-EFFECTIVE SYNTHESIS OF UBIQUINONES | ZYMES, LLC (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20060167289-A1 | Practical, cost-effective synthesis of ubiquinones | ZYMES, LLC (US) | 2006-07-27 | — | — | US | disclosed |
| US-6927184-B1 | Method of producing microfiber nonwovens that contain cycloolefin polymers | TICONA GMBH (DE) | 2005-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080086013-A1 | CARBOMETALLATION OF ALKYNES AND IMPROVED SYNTHESIS OF UNIQUINONES | NDUFA10, NDUFB10, NDUFV1 | CHRM2 1998/4885CHRM1 1849/4885CHRM3 803/4885 |
| US-20060167289-A1 | Practical, cost-effective synthesis of ubiquinones | SQOR, NDUFS6, NDUFS5 | CHRM2 3761/4885CHRM1 3954/4885CHRM3 2970/4885 |
| US-20090131705-A1 | Practical, Cost-Effective Synthesis of Ubiquinones | SQOR, NDUFS6, NDUFS5 | CHRM2 3761/4885CHRM1 3954/4885CHRM3 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.